Overview

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Status:
Active, not recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Cookies for Kids' Cancer
North American Consortium for Histiocytosis
Sanofi
St. Baldrick's Foundation

Treatments:

Clofarabine